Reuters logo
8 months ago
BRIEF-Shire says topline results of Phase 3 investigational study of Vonvendi meets primary endpoint
December 2, 2016 / 4:16 PM / 8 months ago

BRIEF-Shire says topline results of Phase 3 investigational study of Vonvendi meets primary endpoint

1 Min Read

Dec 2 (Reuters) - Shire Plc :

* Topline results of Phase 3 investigational study of Vonvendi [von Willebrand factor (recombinant)] meets primary endpoint effectively controlling bleeding and blood loss during surgical procedures

* Vonvendi is also being studied for prophylaxis and pediatric indications

* Results of Phase 3 investigational study of Vonvendi Willebrand factor meets primary endpoint

* Results from Phase 3 investigational study to be used to support filing for regulatory approvals in Europe in 2017 and in other markets globally Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below